EGLN1 and polycythemia: This discovery could be significant for certain pathologies where the erythropoietic effect is not desirable, such as secondary congenital erythrocytosis where disease develops due to mutations in genes regulating Epo such as VHL, EGLN1, EPAS1, or EPO [65].